CN109311831A - 4-苯基噻唑衍生物的晶型及其制备方法 - Google Patents

4-苯基噻唑衍生物的晶型及其制备方法 Download PDF

Info

Publication number
CN109311831A
CN109311831A CN201880002130.5A CN201880002130A CN109311831A CN 109311831 A CN109311831 A CN 109311831A CN 201880002130 A CN201880002130 A CN 201880002130A CN 109311831 A CN109311831 A CN 109311831A
Authority
CN
China
Prior art keywords
crystal form
solvent
peak
compound
formulas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880002130.5A
Other languages
English (en)
Other versions
CN109311831B (zh
Inventor
王天明
伍伟
陈鹏
李宏名
庹世川
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Original Assignee
Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Pharmaceutical Research Institute Co Ltd filed Critical Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Publication of CN109311831A publication Critical patent/CN109311831A/zh
Application granted granted Critical
Publication of CN109311831B publication Critical patent/CN109311831B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了4‑苯基噻唑衍生物的晶型、包含其的药物组合物、制备方法以及所述晶型在制备用于治疗慢性肝病相关的血小板减少(TLD)的药物中的用途。式I。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201880002130.5A 2017-02-14 2018-02-02 4-苯基噻唑衍生物的晶型及其制备方法 Active CN109311831B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710078118 2017-02-14
CN201710078118X 2017-02-14
PCT/CN2018/075066 WO2018149309A1 (zh) 2017-02-14 2018-02-02 4-苯基噻唑衍生物的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN109311831A true CN109311831A (zh) 2019-02-05
CN109311831B CN109311831B (zh) 2021-07-09

Family

ID=63169705

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880002130.5A Active CN109311831B (zh) 2017-02-14 2018-02-02 4-苯基噻唑衍生物的晶型及其制备方法

Country Status (2)

Country Link
CN (1) CN109311831B (zh)
WO (1) WO2018149309A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970678A (zh) * 2017-12-28 2019-07-05 四川科伦药物研究院有限公司 4-苯基噻唑衍生物无定形及其制备方法和用途
CN112166107A (zh) * 2018-06-08 2021-01-01 四川科伦药物研究院有限公司 4-苯基噻唑衍生物的晶型及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1419547A (zh) * 2000-01-24 2003-05-21 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
CN1863783A (zh) * 2003-08-12 2006-11-15 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
CN101809008A (zh) * 2007-07-31 2010-08-18 盐野义制药株式会社 含有具血小板生成素受体激动作用的光学活性化合物的药物组合物及其中间体
CN105992761A (zh) * 2013-12-20 2016-10-05 盐野义制药株式会社 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法
CN106083759A (zh) * 2016-06-15 2016-11-09 上海丸全化学科技有限公司 一种芦曲泊帕的全新合成工艺
CN106565625A (zh) * 2016-11-04 2017-04-19 杭州励德生物科技有限公司 一种抗血小板减少症新药Lusutrombopag中间体的制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1419547A (zh) * 2000-01-24 2003-05-21 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
CN1863783A (zh) * 2003-08-12 2006-11-15 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
CN101809008A (zh) * 2007-07-31 2010-08-18 盐野义制药株式会社 含有具血小板生成素受体激动作用的光学活性化合物的药物组合物及其中间体
CN105992761A (zh) * 2013-12-20 2016-10-05 盐野义制药株式会社 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法
CN106083759A (zh) * 2016-06-15 2016-11-09 上海丸全化学科技有限公司 一种芦曲泊帕的全新合成工艺
CN106565625A (zh) * 2016-11-04 2017-04-19 杭州励德生物科技有限公司 一种抗血小板减少症新药Lusutrombopag中间体的制备方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970678A (zh) * 2017-12-28 2019-07-05 四川科伦药物研究院有限公司 4-苯基噻唑衍生物无定形及其制备方法和用途
CN109970678B (zh) * 2017-12-28 2024-03-08 四川科伦药物研究院有限公司 4-苯基噻唑衍生物无定形及其制备方法和用途
CN112166107A (zh) * 2018-06-08 2021-01-01 四川科伦药物研究院有限公司 4-苯基噻唑衍生物的晶型及其制备方法
CN112166107B (zh) * 2018-06-08 2023-10-27 四川科伦药物研究院有限公司 4-苯基噻唑衍生物的晶型及其制备方法

Also Published As

Publication number Publication date
CN109311831B (zh) 2021-07-09
WO2018149309A1 (zh) 2018-08-23

Similar Documents

Publication Publication Date Title
US20230339885A1 (en) Amorphous form of tetracyclic compound
JP6756617B2 (ja) Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
DK2414356T3 (en) PROPAN-1-sulfonic acid {3- [5- (4-CHLORO-PHENYL) -1H-pyrrolo [2,3-b] pyridine-3- carbonyl] -2,4-difluorophenyl) -AMIDSAMMENSÆTNINGER AND USES THEREOF
JP6313286B2 (ja) 短時間作用型ベンゾジアゼピンを含む組成物
JP5536753B2 (ja) ベンダムスチン塩酸塩の新規固体形態
CN109996787B (zh) 难溶性复合物或其溶剂合物、药物组合物及其应用
CN109311831A (zh) 4-苯基噻唑衍生物的晶型及其制备方法
US10323035B2 (en) Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
US20230183205A1 (en) Pharmaceutical composition in which production of impurities is suppressed
TW201920160A (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
TW202039511A (zh) Mcl-1抑制劑之新結晶型, 其製備方法及包含其之醫藥組合物
WO2021008486A1 (zh) 肌松拮抗的新化合物
CN113631542B (zh) 一种芳香族化合物的固体形式及其制备方法
CN116983271A (zh) 免疫蛋白酶体抑制剂配制物
CN112119073A (zh) 阿贝西尼的固态形式、其用途和制备
WO2020131000A1 (en) Pharmaceutical compound, the method of its making and use as medicinal agent
CN112105622B (zh) 丙戊酸磷脂衍生物的晶型及其制备方法
CN112166107A (zh) 4-苯基噻唑衍生物的晶型及其制备方法
CN111349076B (zh) 一种苯并哌啶类衍生物的l-赖氨酸盐的晶型及其制备方法
JP7431815B2 (ja) トレオスルファンの結晶形
BR122024012946A2 (pt) Composto, composição farmacêutica, uso de uma composição farmacêutica e uso de um composto
WO2024023796A1 (en) Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof
TW202434238A (zh) 苯並氮雜芳環衍生物的鹽、晶型及其在醫藥上的應用
EP3333154A1 (en) Crystalline form of a selective 5-ht6 receptor antagonist
CN111918869A (zh) 甘草酸衍生物的结晶、其结晶组合物、药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant